Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for MorphoSys?
MorphoSys's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -14.75. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for MorphoSys's stock?
Currently, 1 analysts cover MorphoSys's stock, with a consensus target price of $79.42. Analyst ratings provide insights into the stock's expected performance.
What is MorphoSys's revenue over the trailing twelve months?
Over the trailing twelve months, MorphoSys reported a revenue of $214.94M.
What is the EBITDA for MorphoSys?
MorphoSys's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$504.04M. EBITDA measures the company's overall financial performance.
What is the free cash flow of MorphoSys?
MorphoSys has a free cash flow of -$334.26M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does MorphoSys have, and what sector and industry does it belong to?
MorphoSys employs approximately 564 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
Financials
- EPS (TTM)
- -14.75
- Revenue (TTM)
- $214.94M
- EBITDA (TTM)
- -$504.04M
- Free Cashflow (TTM)
- -$334.26M
Analyst Ratings
The price target is $79.42 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
- Employees
- 564
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- DE0006632003
- Primary Ticker
- MOR
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet